University of Balamand - Lebanon
State University of New York at Buffalo
Roswell Park Cancer Institute
Internal Medicine and Medical Oncology, American Board of Internal Medicine
Dr. Francis received a Bachelor of Sciences from the American University of Beirut and then continued on to medical school at the University of Balamand - Lebanon.
After completing a postdoctorate laboratory research fellowship in Cancer Experimental Therapeutics at Loma Linda University Medical Center in Southern California, Dr. Francis went for his Internal Medicine Residency at State University of New York (SUNY) at Buffalo-University at Buffalo Department of Medicine. While at SUNY, Dr. Francis served as a chief resident and earned the "Rakesh Bidani Memorial Award" for his selfless commitment to teaching, dedication to patients and support of colleagues. He then went to pursue a Medical Oncology Clinical Fellowship at Roswell Park Cancer Institute in Buffalo, New York.
Dr. Francis' clinical interests focus on treating various types of hematological malignancies and solid tumors, with a specific focus on lung cancer. During his fellowship at Roswell Park Cancer Institute, he studied and researched novel agents in the treatment of non-small cell lung cancer.His most recent publications include:
CD19 expression in acute leukemia is not restricted to the cytogenetically aberrant populations.
Francis J, Dharmadhikari AV, Sait SN, Deeb G, Wallace PK, Thompson JE, Wang ES, Wetzler M.
Leuk Lymphoma. 2012 Nov 29. [Epub ahead of print] PMID:23193950
Aminoflavone induces oxidative DNA damage and oxidative stress mediated cell death in breast cancer cells: McLean, et al. International Journal of Cancer 2008 Apr 1;122(7):1665-74
Detection of extra-medullary relapse of acute lymphoblastic leukemia by radiographic imaging following allogeneic hematopoietic SCT. Francis, et al. Bone Marrow Transplant. 2009 Dec,44(12):827-8. Epub Jul 27
Reversible cardiotoxicity with tyrosine kinase inhibitors. Francis, et al. Clinl Adv Hematol Oncol. 2010 Feb
Treating myelodysplatic syndrome improves an accompanying autoimmune disease along with reduction in Regulatory T-cells. Ustwani, et al. Leuk Res 2011 Jan 17